Tag
#XOMA
-
2026
-
XOMA – SCHEDULE 13D/A [Amend]
-
XOMA – DEFA14A
-
XOMA – 8-K
-
XOMA – 10-Q
-
XOMA – SCHEDULE 13D/A [Amend]
-
XOMA – DEFA14A
-
XOMA – 8-K/A [Amend]
-
XOMA – DEFA14A
-
XOMA – 8-K
-
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
-
XOMA – DEFA14A
-
XOMA – DEF 14A
-
XOMA Royalty Declares Quarterly Preferred Stock Dividends
-
XOMA Royalty Declares Quarterly Preferred Stock Dividends
-
XOMA – 10-K
-
XOMA – 8-K
-
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
-
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
-
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
-
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
-
XOMA – 8-K
-
XOMA Royalty to Present at Investor Conferences in March
-
XOMA – SCHEDULE 13G/A [Amend]
-
XOMA – 8-K
-
XOMA – SC TO-T/A [Amend]